KalVista Pharmaceuticals, Inc. 8-K

What Happened
KalVista Pharmaceuticals (KALV) filed an 8‑K on June 11, 2026 reporting the closing of its merger with Chiesi (the “Merger”), effective June 11, 2026. As part of the closing, KalVista and the trustee under its 3.250% Convertible Senior Notes due 2031 amended the indenture so each $1,000 principal amount of those notes may be converted into cash equal to $1,606.28. The filing also discloses termination of the company’s equity plans, a full board turnover with the Purchaser’s director becoming KalVista’s sole director, and certain transaction payments and agreements for executives.

Key Details

• Convertible notes: supplemental indenture provides cash conversion of $1,606.28 per $1,000 principal (Conversion Rate × Merger Consideration); a “unit of Reference Property” is defined as $27.00 in cash.
• Equity plans terminated (effective at or immediately prior to the Effective Time): Company 2015 Incentive Plan, 2017 Equity Incentive Plan, 2021 Equity Inducement Plan, and the 2017 Employee Stock Purchase Plan.
• Board and management changes: directors Brian J. G. Pereira, Benjamin L. Palleiko, William Fairey, Laurence Reid, Bethany Sensenig, Nancy Stuart, Patrick Treanor and Edward W. Unkart resigned; John Hess (Purchaser’s sole director) became the company’s sole director and an officer at the Effective Time. Resignations were not due to disagreements with management.
• Executive payments and agreements: Transaction Bonus Agreements (entered June 8, 2026) pay lump sums within 60 days of the Effective Time — $5,070,000 to Benjamin Palleiko (CEO), $2,930,000 to Paul Audhya (CMO), and $2,500,000 to Brian Piekos (CFO). On June 11, 2026 the company entered a Gross‑Up Agreement with CFO Brian Piekos to cover any Section 4999 excise tax on parachute payments; the potential reimbursement amount is currently unknown.
• Change in control: Parent (Chiesi) acquired control of KalVista; the merger consideration was funded with Parent’s cash on hand and financing.

Why It Matters

• For shareholders: the merger represents a change in control and likely ends KalVista’s standalone public-company governance and equity‑grant programs (terminated plans). Shareholders should expect the company to operate under Parent’s control going forward.
• For convertible noteholders: the amended indenture fixes a cash conversion value ($1,606.28 per $1,000) that determines their payout option following the Merger.
• For company cash flow and compensation: the disclosed transaction bonuses and the potential gross‑up payment to the CFO are material cash obligations in the near term; the exact gross‑up exposure is uncertain and depends on tax rules and mitigation strategies.
• Governance risk/clarity: the entire board was replaced at closing but resignations were not due to disputes with management, reducing the risk of disclosed governance conflicts in the filing.